Clinical trials: Sorafenib
Adult Primary Hepatocellular Carcinoma, Localized Resectable Adult Primary Liver Cancer
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
The purpose of this study is to determine if sorafenib (sorafenib tosylate) is a safe and effective treatment option for preventing liver cancer in high risk patients following liver transplantation.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT01624285
- Testing
- sorafenib tosylate, laboratory biomarker analysis
- Where
- 21 sites in United States
- Volunteers
- 20 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Hepatocellular Carcinoma
Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
This research study will evaluate Sorafenib (Nexavar®) and Capecitabine (Xeloda®) to see the following: how effective this combination of study drugs will be in treating HCC how long subjects respond to these study drugs what…
- Trial name
- NCT01032850
- Testing
- Sorafenib & Capecitabine
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- New Mexico Cancer Research Alliance
Hepatocellular Carcinoma
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma
It has been shown previously that gene expression profiling signature (a set of dysregulated genes) can be used for molecular classification, diagnosis, and prognosis of several types of cancers.
- Trial name
- NCT02733809
- Testing
- Sorafenib
- Where
- Saudi Arabia
- Volunteers
- 40 people
- Sponsor
- King Saud University
Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma
Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer
Sorafenib may stop the growth of tumor cells by stopping blood flow to the tumor and by blocking the enzymes necessary for their growth.
- Trial name
- NCT00093626
- Testing
- Laboratory Biomarker Analysis, Sorafenib Tosylate
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin plus fluorouracil/leucovorin compared with HAIC of oxaliplatin alone in patients with hepatocellular…
- Trial name
- NCT03468231
- Testing
- Sorafenib, HAIC of FOLFOX, HAIC of OXA
- Where
- 7 sites in China
- Volunteers
- 300 people
- Sponsor
- Sun Yat-sen University
Ovarian Cancer
Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer
The goal of this type of clinical trial study is to evaluate the safety and efficacy of Surufatinib combined with Carboplatin/Paclitaxel and Surufatinib combined with Olaparib as first-line and maintenance therapy for newly…
- Trial name
- NCT06437353
- Testing
- Paclitaxel
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Anhui Provincial Cancer Hospital
Hepatocellular Carcinoma Non-resectable
TACE Combined With Sorafenib and Tislelizumab for Advanced HCC
This study will evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with sorafenib and tislelizumab in patients with advanced hepatocellullar carcinoma (HCC).
- Trial name
- NCT04599777
- Testing
- TACE combined with sorafenib and tislelizumab
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma
Efficacy of Localized Concurrent Chemo-radiation Therapy and Sorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma
This is a single-center, single-arm, open-label, prospective phase 2 trial to assess the efficacy of localized concurrent chemoradiation therapy (CCRT) and sorafenib sequential therapy in subjects with advanced HCC.
- Trial name
- NCT02425605
- Testing
- CCRT, sorafenib
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Yonsei University
Carcinoma, Renal Cell
BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma
The purpose of the study is to: Find out if patients receiving BAY43-9006 will live longer without tumor progression than those receiving standard therapy with interferon alpha-2a Find out if a higher dose of BAY43-9006 can…
- Trial name
- NCT00117637
- Testing
- Sorafenib (Nexavar, BAY43-9006), Interferon
- Where
- 42 sites in United States, France and 5 more
- Volunteers
- 189 people
- Sponsor
- Bayer
Metastatic Renal Cell Carcinoma
Second Line Sorafenib After Pazopanib in Patients With RCC
Retrospective studies showed Sorafenib's efficacy as second line treatment after a Tyrosine Kinase Inhibitor (TKI). Currently there is no standard of treatment in 2nd line for patients treated in first line with pazopanib for…
- Trial name
- SOAP (NCT02122003)
- Testing
- Sorafenib
- Where
- Italy
- Volunteers
- 16 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Metastatic Renal Cell Carcinoma
Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients
There is no standard treatment in patients with renal cell carcinoma that was previously treated with VEGF targeted therapies and mTOR inhibitors.So investigators conducted a randomized, open-label, multi-center phase II study to…
- Trial name
- NCT02330783
- Testing
- Bevacizumab, Sorafenib
- Where
- 4 sites in China
- Volunteers
- 106 people
- Sponsor
- Peking University Cancer Hospital & Institute
Kidney Cancer
Sorafenib in Treating Patients Undergoing Surgery for Stage II, Stage III, or Stage IV Kidney Cancer
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NRR (NCT00405366)
- Testing
- sorafenib tosylate
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Refractory Malignancy
Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid Tumors
This is a phase I, randomized, safety and pharmacokinetic (PK) study of sorafenib given in combination with capecitabine. The study will enroll two simultaneous cohorts; patients will be randomly assigned to either Cohort A or…
- Trial name
- NCT00613145
- Testing
- Capecitabine and Sorafenib
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- SCRI Development Innovations, LLC
Hepatocellular Carcinoma
A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver
To determine if IMC-A12 given in combination with Sorafenib is safe and effective for participants with advanced liver cancer.
- Trial name
- NCT00906373
- Testing
- IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg), IMC-A12 (cixutumumab) - 20 mg/kg, Sorafenib
- Where
- 7 sites in United States
- Volunteers
- 47 people
- Sponsor
- Eli Lilly and Company
Metastatic or Locally Advanced Solid Tumors
EVESOR: a Phase 1 Trial of Everolimus and Sorafenib
EVESOR multiparameter phase I trial aims at determining the safety of different doses and dosing schedules of everolimus in combination with sorafenib as well as the recommended doses \& dosing schedules for phase 2 trials in…
- Trial name
- EVESOR (NCT01932177)
- Testing
- Everolimus and sorafenib
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Hospices Civils de Lyon
Advanced Solid Tumors
Sorafenib in Combination With RAD001 in Advanced Solid Tumors Selected on Molecular Targets
Sorafenib is an oral multikinase inhibitor and among its targets are several RTKs involved in tumor genesis (Raf, Flt-3, c-Kit and RET) and angiogenesis (VEGFR1, 2 and 3 and PDGFRß).
- Trial name
- NCT01226056
- Testing
- RAD001 in combination with sorafenib
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- Southern Europe New Drug Organization
Locally Metastatic Malignant Neoplasm
Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC)
This is a phase II trial that follows the completion of the phase I UCSF trial of everolimus and sorafenib for Renal Cell Carcinoma (RCC). This trial will be for patients who have not had treatment for RCC before.
- Trial name
- NCT01616186
- Testing
- Everolimus and sorafenib, Sunitinib monotherapy
- Sponsor
- Andrea Harzstark
Unresectable Hepatocellular Cancer, Portal Vein Tumor Thrombus
Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor Thrombus
This study aims to evaluate the efficacy and safety of sorafenib plus toripalimab for unresectable hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT).
- Trial name
- STUHCCPVTT (NCT04069949)
- Testing
- sorafenib; toripalimab
- Volunteers
- 39 people
- Sponsor
- Sichuan University
Refractory Solid Tumor, Hepatocellular Carcinoma
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
This is a phase I/II study to evaluate the safety of combining intravenous (IV) atezolizumab and bevacizumab every three weeks, with daily oral cyclophosphamide and pharmacokinetic (PK)-guided sorafenib in children and adolescent…
- Conditions
- Refractory Solid Tumor, Hepatocellular Carcinoma, Malignant Solid Tumor, Pediatric Cancer
- Trial name
- NCT05468359
- Testing
- Atezolizumab, Sorafenib, Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- St. Jude Children's Research Hospital
Hepatocellular Carcinoma
Safety Study of Sorafenib Following Combined Therapy of Radiation and TACE for Liver Cancer
Patients with liver cancer will receive interventional therapy plus radiotherapy. Maintenance Sorafenib will be taken after the completion of radiotherapy.
- Trial name
- NCT00999843
- Testing
- Sorafenib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University